Shire Share News (SHP)

Broker tips: Shire, GKN, IG Group

(ShareCast News) - UBS downgraded Shire to 'neutral' from 'buy' and cut the price target to 5,000p from 5,600p saying a tougher environment for expensive orphan drugs was likely to constrain performance. This, and other issues such as low return on invested capital and the 2023 Vyvanse patent expiry

UBS downgrades Shire on orphan drug concerns

(ShareCast News) - UBS downgraded Shire to 'neutral' from 'buy' and cut the price target to 5,000p from 5,600p saying a tougher environment for expensive orphan drugs was likely to constrain performance. This, and other issues such as low return on invested capital and the 2023 Vyvanse patent expiry

BUZZ-European Pharma: UBS shuffles recommendations

** UBS analysts say investors in healthcare stocks should seek exposure to oncology and new expensive drugs which displace older expensive drugs; avoid therapy areas at risk of becoming crowded and new drugs with high budget impact ** Brokerage double upgrades to "buy" from "sell" Novo Nord

BROKER RATINGS SUMMARY: Credit Suisse Raises Rio Tinto And Cuts BHP

LONDON BRIEFING: Pound Slips As UK's May Asks For Article 50 Support

Pharma stocks to outperform versus Miners as US dollar gains, Deutsche Bank says

(ShareCast News) - Pharmaceuticals' recent underperformance versus Mining stocks might be set to end, strategists at Deutsche Bank said. The approximately 5% gain in the US dollar index over the past three months would have been consistent with double-digit outperformance by the former, the investme

Actelion's ambitious independent-minded CEO will drive up takeover price

* Need for premium could lift price to $26 bln, analysts say * J&J has had preliminary talks with Swiss biotech firm * Actelion could also appeal to deal-hungry Sanofi By John Miller ZURICH, Nov 28 (Reuters) - Actelion Chief Executive Jean-Paul Clozel's desire to keep Euro

Shire to build innovation hub in Massachusetts

(ShareCast News) - Irish pharmaceutical company Shire announced that it will expand its operations in Cambridge, Massachusetts through the establishment of an innovation hub to study rare diseases. Shire and BioMed Realty have signed a lease for a 343,00 square foot building at 500 Kendall street ca

REUTERS SUMMIT-Omega's Einhorn sees Trump's policies boosting stocks

LONDON MARKET MIDDAY: Trump Rally Cools Ahead Of Risk-Off Weekend

Shire sees opportunity in Asia, aims to double revenue by 2020

By Clara Ferreira-Marques SINGAPORE, Nov 11 (Reuters) - Shire, a specialist in rare diseases, aims to double Asian sales by 2020, as it targets markets including China, where it hopes to put its haemophilia drugs on a reimbursement list being updated this year for the first time since 2009.

Friday broker round-up

(ShareCast News) - Imperial Brands: JP Morgan keeps at neutral with a target price of 3660p. Standard Life: Berenberg stays at buy 416p target. Barclays: Societe Generale upgrades to buy with a 235p target. UBM: Barlcays reiterates equal-weight with a 755p target. Derwent London: Goldman Sachs ke

UPDATE 4-Pharma, biotech shares soar as Trump win calms pricing talk

* Clinton had been seen more likely to rein in drug costs * California drug pricing initiative heading for defeat * Hospital shares crushed on Obamacare rollback worries (Adds background on biotechs, analyst comment, updates share moves) By Lewis Krauskopf and Ben HirschlerRead more

Britain's FTSE recovers from Trump shock to hit one-week high

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 index closes 1 pct higher * Miners, pharma stocks rally * U.S.-exposed firms also gain By Atul Prakash and Kit R

Sector movers: Miners, US election-related plays lead gains

(ShareCast News) - Steel and mining stocks led gains for another session, amid widespread gains for most base metals and coal, helped by an initial bout of weakness in the US dollar. As of 1650 GMT, the US dollar was trading higher by 0.47% to 98.32 points after having earlier hit an intra-day low a